Navigation Links
BioMS Medical's pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
Date:12/14/2007

Toronto Stock Exchange Symbol: MS

EDMONTON, Dec. 14 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that following the meeting of the independent Data Safety Monitoring Board (DSMB), the Company has received a recommendation to continue MAESTRO-01, its pivotal phase II/III clinical trial for MBP8298 for the treatment of secondary progressive multiple sclerosis.

This was the eighth of several regularly scheduled reviews by the DSMB, including the planned in-depth interim safety analysis, held in April 2007, on the first 100 patients enrolled in the study who had completed twelve months of treatment. The purpose of the DSMB is to provide objective, independent safety monitoring of the trial.

About BioMS Medical Corp.

-------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, MBP8298, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. For further information please visit our website at http://www.biomsmedical.com.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditio
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. Genmab Amends Ofatumumab Pivotal Study in NHL to Single Arm Study
10. ZymoGenetics and Merck Serono Receive FDA Special Protocol Assessment for Atacicept Pivotal Study in Lupus Nephritis
11. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014  Bill Jacobs Automotive, a group of car dealerships ... with the Heartland Blood Center and offering free oil change ... takes place Saturday, Jan. 18 at the Bill Jacobs Cadillac ... (Photo: http://photos.prnewswire.com/prnh/20140115/MN46637 )  The Bill ...
(Date:1/15/2014)... FALLS, N.Y., Jan. 15, 2014   Niagara Thermal Products ... by Buffalo BioBlower Technologies LLC ("B3") as the critical ... 2 award from the Army Corps of Engineers.  B3 ... kills all biological contaminants and destroys VOCs and other ...
(Date:1/15/2014)... Village, Calif. (PRWEB) January 15, 2014 ... treatment and management through the genomic analysis of tumor ... offer Therapy Finder™, a web-based cancer decision support application ... reporting option with Cynvenio’s ClearID™ genomic test, Therapy Finder ...
(Date:1/15/2014)... 2014 ­ RedBrick Health , a fast-growing leader ... announces that EmblemHealth , the New ... now providing the RedBrick Compass health assessment, combined with ... of its members. EmblemHealth is among the first health ...
Breaking Biology Technology:Join the Bill Jacobs Auto blood drive and receive a free oil change 2Niagara Thermal Products LLC Selected as Critical Supplier for Buffalo BioBlower Air Purification Systems 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3
... Technology experts from over 20 countries are in ... environment, topics of global importance and immediacy. The ... forum to discuss initiatives in micromachining and nano ... economic and social outcomes. , The Summit promotes ...
... 6 Dendreon Corporation (Nasdaq: DNDN ) today reported ... for the first quarter of 2009 was $30,000 compared to $31,000 ... expenses for the three months ended March 31, 2009 were $17.0 ... The net loss for the quarter ended March 31, 2009 ...
... just six atoms thick in which electrons appear to ... their direction of travel has been discovered by a ... Working with computational models, the team has found that ... sandwiched between insulating sheets of titanium dioxide exhibit one ...
Cached Biology Technology:World Micromachine Summit highlights technologies impacting energy and the environment 2Dendreon Reports First Quarter 2009 Financial Results 2Dendreon Reports First Quarter 2009 Financial Results 3Dendreon Reports First Quarter 2009 Financial Results 4Dendreon Reports First Quarter 2009 Financial Results 5Nano-sandwich triggers novel electron behavior 2Nano-sandwich triggers novel electron behavior 3
(Date:4/23/2014)... have added "playwright" to their resumes in an effort ... onslaught of ethical issues as genomic science transitions to ... first sequenced. , Until now the plays of ... performed for, and by, their peers and others in ... classrooms. With Oxford University Press, publication of the ...
(Date:4/23/2014)... A new study from the Indiana University School of ... consumption and heart disease by finding a strong association ... deadly coronary heart disease. , The study found that ... disease by 57 percent, while no association was found ... non-meat sources, and coronary heart disease. , The study ...
(Date:4/23/2014)... Scarborough research shows that male black widow spiders prefer ... rare example of mate preference by male spiders. ... MacLeod and Maydianne Andrade, a professor in UTSC,s Department ... and the wild that males overwhelmingly chose to mate ... widows can tell whether a potential mate is well-fed ...
Breaking Biology News(10 mins):Bioethicists use theatrical narratives to bridge the gap between society and science 2Bioethicists use theatrical narratives to bridge the gap between society and science 3Study: Iron consumption can increase risk for heart disease 2Picky male black widow spiders prefer well-fed virgins 2
... team of scientists from the Johns Hopkins University ... method to accurately predict dengue fever outbreaks several ... method, known as PRedicting Infectious Disease Scalable Model ... socio-political data in Peru and in the Philippines. ...
... Neck, NY) The Brain & Behavior Research Foundation ... Schizophrenia and Depression) has announced approximately $4 million in ... close to $300 million in research to identify the ... illness. From about 500 applicants, forty research scientists ...
... Reportlinker.com announces that a new market research report ... Hand Geometry Industry http://www.reportlinker.com/p01139076/Global-Hand-Geometry-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Security_Systems ... in US$ Thousands. The report provides separate comprehensive analytics ... Japan , Europe , ...
Cached Biology News:APL novel method accurately predicts disease outbreaks 2Brain & Behavior Research Foundation awards nearly $4 million in new NARSAD grants 2Brain & Behavior Research Foundation awards nearly $4 million in new NARSAD grants 3Brain & Behavior Research Foundation awards nearly $4 million in new NARSAD grants 4Brain & Behavior Research Foundation awards nearly $4 million in new NARSAD grants 5Brain & Behavior Research Foundation awards nearly $4 million in new NARSAD grants 6Brain & Behavior Research Foundation awards nearly $4 million in new NARSAD grants 7Brain & Behavior Research Foundation awards nearly $4 million in new NARSAD grants 8Brain & Behavior Research Foundation awards nearly $4 million in new NARSAD grants 9Brain & Behavior Research Foundation awards nearly $4 million in new NARSAD grants 10Brain & Behavior Research Foundation awards nearly $4 million in new NARSAD grants 11Brain & Behavior Research Foundation awards nearly $4 million in new NARSAD grants 12Global Hand Geometry Industry 2Global Hand Geometry Industry 3Global Hand Geometry Industry 4Global Hand Geometry Industry 5Global Hand Geometry Industry 6Global Hand Geometry Industry 7Global Hand Geometry Industry 8Global Hand Geometry Industry 9
2,4-Dinitrophenyl hapten is conjugated to BSA (Bovine Serum Albumin) protein through lysine....
4-Hydroxy-3-iodo-5-nitrophenylacetyl hapten is conjugated to BSA protein through lysine by amide bonds....
Amino Acid Analysis is performed using ion-exchange separation of the amino acids from acid hydrolysates, followed by ninhydrin detection. Typical quantities required are 0.1 to 0.5 mg, depending on...
2,4,6-Trinitrophenyl hapten is conjugated to Bovine Serum Albumin protein through lysine by amide bonds....
Biology Products: